within Pharmacolibrary.Drugs.ATC.C;

model C01AC01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.5e-05,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0002,
    k12             = 0.43,
    k21             = 0.43
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01AC01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>G-strophanthin, also known as ouabain, is a cardiac glycoside used historically for the treatment of heart failure and arrhythmias. Its modern clinical use is rare or limited to certain regions and research settings, as safer alternatives have largely replaced it.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults, as no direct population PK studies could be found for human clinical use; the values are approximated based on older pharmacologic literature, secondary reviews, and knowledge of intravenous administration in acute heart failure.</p><h4>References</h4><ol><li><p>Greeff, K (1977). [Pharmacokinetics of g-strophanthin]. <i>Deutsche medizinische Wochenschrift (1946)</i> 102(4) 135–139. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/832594/&quot;>https://pubmed.ncbi.nlm.nih.gov/832594</a></p></li><li><p>Erdle, HP, et al., &amp; Gross, F (1979). [Absorption and excretion of g-strophanthin after intravenous or sublingual administration (author&#x27;s transl)]. <i>Deutsche medizinische Wochenschrift (1946)</i> 104(27) 976–979. DOI:<a href=&quot;https://doi.org/10.1055/s-0028-1129021&quot;>10.1055/s-0028-1129021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/456272/&quot;>https://pubmed.ncbi.nlm.nih.gov/456272</a></p></li><li><p>Prandota, J (2001). Clinical pharmacology of furosemide in children: a supplement. <i>American journal of therapeutics</i> 8(4) 275–289. DOI:<a href=&quot;https://doi.org/10.1097/00045391-200107000-00010&quot;>10.1097/00045391-200107000-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11441327/&quot;>https://pubmed.ncbi.nlm.nih.gov/11441327</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01AC01;
